γ Interferon transduced 9L gliosarcoma. Cytokine gene therapy and its relevance to cellular therapy with alloreactive cytotoxic T lymphocytes

[1]  L. D.,et al.  Brain tumors , 2005, Psychiatric Quarterly.

[2]  D. Bellgrau,et al.  Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors , 2005, Journal of Neuro-Oncology.

[3]  D. Bellgrau,et al.  Allogeneic tumor-specific cytotoxic T lymphocytes , 2005, Cancer Immunology, Immunotherapy.

[4]  P. Subramaniam,et al.  Inhibition of the Glioblastoma Cell Cycle by Type I IFNs Occurs at Both the G1 and S phases and Correlates With the Upregulation of P21WAF1/CIP1 , 2000, Journal of Neuro-Oncology.

[5]  M. Gore,et al.  Purified herpes simplex virus thymidine kinase retroviral particles: , 2002, Cancer Gene Therapy.

[6]  C. Kruse,et al.  Strategies using the immune system for therapy of brain tumors. , 2001, Hematology/oncology clinics of North America.

[7]  T. Lichtor,et al.  Immunotherapy Task Force for malignant brain tumors. April 21, 2001, Toronto, Ontario. , 2001, Neuro-oncology.

[8]  J. Fabre.  The allogeneic response and tumor immunity , 2001, Nature Medicine.

[9]  D. B. Paul,et al.  Immunologic approaches to therapy for brain tumors , 2001, Current neurology and neuroscience reports.

[10]  Carol A. Kruse,et al.  Cytotoxic T-Lymphocytes Reactive to Patient Major Histocompatibility Complex Proteins for Therapy of Brain Tumors , 2001 .

[11]  A. Wiegmans,et al.  The treatment of established intracranial tumors by in situ retroviral IFN-γ transfer , 2000, Gene Therapy.

[12]  M. Prados,et al.  Biology and treatment of malignant glioma. , 2000, Seminars in oncology.

[13]  P. Subramaniam,et al.  Inhibitory Effects of IFN-γ and Acyclovir on the Glioblastoma Cell Cycle , 2000 .

[14]  B. Kleinschmidt-DeMasters,et al.  Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms , 2000, Cancer Gene Therapy.

[15]  P. Subramaniam,et al.  Inhibitory effects of IFN-gamma and acyclovir on the glioblastoma cell cycle. , 2000, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  A. Wiegmans,et al.  The treatment of established intracranial tumors by in situ retroviral IFN-gamma transfer. , 2000, Gene therapy.

[17]  M. Oldstone,et al.  Detailed in vivo analysis of interferon-gamma induced major histocompatibility complex expression in the the central nervous system: astrocytes fail to express major histocompatibility complex class I and II molecules. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[18]  P. Subramaniam,et al.  IFNγ inhibition of cell growth in glioblastomas correlates with increased levels of the cyclin dependent kinase inhibitor p21WAF1/CIP1 , 1998, Oncogene.

[19]  S. Pestka,et al.  Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. , 1998, Immunity.

[20]  J. Stears,et al.  Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 , 1997, Cancer Immunology, Immunotherapy.

[21]  S. Tseng,et al.  Induction of Antitumor Immunity by Intracerebrally Implanted Rat C6 Glioma Cells Genetically Engineered to Secrete Cytokines , 1997, Journal of immunotherapy.

[22]  C. Kruse,et al.  Artificial‐capillary‐systemdevelopment of human alloreactive cytotoxic T‐lymphocytes that lyse brain tumour , 1997 .

[23]  B. Kleinschmidt-DeMasters,et al.  Purified herpes simplex thymidine kinase Retrovector particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. , 1997, Cancer gene therapy.

[24]  U. Boehm,et al.  Cellular responses to interferon-gamma. , 1997, Annual review of immunology.

[25]  C. Kruse,et al.  Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. , 1997, Biotechnology and applied biochemistry.

[26]  R. Foà,et al.  Retroviral vector-mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect. , 1996, Blood.

[27]  L. Blatt,et al.  Gene therapy with an adeno-associated virus carrying an interferon gene results in tumor growth suppression and regression. , 1996, Cancer gene therapy.

[28]  E. Cohen,et al.  Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. , 1995, Journal of neurosurgery.

[29]  L. Lampson.  Interpreting MHC class I expression and class I/class II reciprocity in the CNS: Reconciling divergent findings , 1995, Microscopy research and technique.

[30]  R. Ramesh,et al.  The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. , 1995, Cancer letters.

[31]  M. Lotze,et al.  Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha. , 1995, Cancer gene therapy.

[32]  E. Gilboa,et al.  RG-2 glioma growth attenuation and severe brain edema caused by local production of interleukin-2 and interferon-gamma. , 1995, Cancer research.

[33]  T. Darrow,et al.  Retrovirus‐Mediated Gene Transfer of the Human γ‐IFN Gene: A Therapy for Cancer , 1994 .

[34]  H. Bear,et al.  gamma-Interferon plays a key role in T-cell-induced tumor regression. , 1993, Cancer research.

[35]  E. Gilboa,et al.  Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. , 1993, Journal of immunology.

[36]  N. Gross,et al.  Differentiation‐related expression of adhesion molecules and receptors on human neuroblastoma tissues, cell lines and variants , 1992, International journal of cancer.

[37]  L. Watkins,et al.  A 9L Gliosarcoma Transplantation Model for Studying Adoptive Immunotherapy into the Brains of Conscious Rats , 1992, Cell transplantation.

[38]  Y. Watanabe.  Transfection of interferon-gamma gene in animal tumors--a model for local cytokine production and tumor immunity. , 1992, Seminars in cancer biology.

[39]  P. Wen,et al.  Effects of γ-interferon on major histocompatibility complex antigen expression and lymphocytic infiltration in the 9L gliosarcoma brain tumor model: implications for strategies of immunotherapy , 1992, Journal of Neuroimmunology.

[40]  E. Oldfield,et al.  Expression and modulation of major histocompatibility antigens on murine primary brain tumor in vitro. , 1991, Journal of neurosurgery.

[41]  L. Lampson,et al.  Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-γ , 1991, Journal of Neuroimmunology.

[42]  E. Gilboa,et al.  Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. , 1990, Cancer research.

[43]  D. Bellgrau,et al.  Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Miyatake,et al.  Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-gamma gene. , 1990, Journal of the National Cancer Institute.

[45]  S. Miyatake,et al.  Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[46]  B. Steiniger,et al.  Rat ependyma and microglia cells express class II MHC antigens after intravenous infusion of recombinant gamma interferon , 1988, Journal of Neuroimmunology.

[47]  T. Gajewski,et al.  Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. , 1988, Journal of immunology.

[48]  W. Hickey,et al.  Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement. , 1986, Journal of immunology.

[49]  R. Grunow,et al.  Recombinant interferon-gamma induces interleukin 2 receptors on human peripheral blood monocytes. , 1986, Journal of immunology.

[50]  S. Ferrone,et al.  Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. , 1984, Cancer research.